Experimental Drug Being Tested for Acute Myeloid Leukemia
Date: June 1, 2004
Blood, January 24, 2004
Investigators are testing an experimental drug that blocks the impact of a gene mutation commonly found in acute leukemia.
The drug, CEP-701, appears to cancel out the effect of mutations of the FLT3 gene, a primary culprit in an aggressive and treatment-resistant form of acute myeloid leukemia (AML). CEP-701 may improve the effectiveness of standard chemotherapy, and a clinical research trial combining the two is now under way for adult patients who have relapsed AML and the FLT3 gene mutation. Recent preliminary studies published in Blood ONLINE show five out of 14 patients treated with CEP-701 experienced decreases in leukemic cells in the bone marrow and circulating blood, and laboratory studies confirmed that the drug blocked the effect of the FLT3 mutation.
For more information about the study, contact B. Douglas Smith, M.D., at 410-614-5068 or firstname.lastname@example.org.
This research is funded by the National Cancer Institute, the Leukemia and Lymphoma Society and the Children’s Cancer Foundation.
Articles in this Issue
- Gene Hunters Pinpoint New Cancer Gene Target
- Faces of Childhood Cancer
- Clinical Trial in the Spotlight
- A Fighting Chance
- A Champion of Pediatric Cancer Research
- One Physician's Quest for a Treatment for the Worst Kind of Pediatric Brain Tumor
- Origin of Multiple Myeloma Found in Rare Stem Cell
- Experimental Drug Being Tested for Acute Myeloid Leukemia
- 'Switched-Off' Genes May Put First Chink in Colon Cell's Anti-Tumor Armor
- Against All Odds: Ariana's Story
- From the Laundry Room to the Laboratory
- In Lauren's Head
- Pediatric Oncology Friends Bring Rhyme and Reason to Pediatric Cancer Research
- Optimists Provide Landmark Gift to Children's Cancer Research
- Eli Kahn
- Possible Interaction Identified Between Tamoxifen and Hot Flash Drug
- Premature Aging Gene Could Have Implications for New Cancer Therapies
- Something's Fishy in Cancer Research
- Angiogenesis Gene Linked to Boimarkers in Breast Cancer
- A Cure is More than the Eradication of Cancer
- Arsenic Part of Novel Treatment for Leukemia